Jing Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jing Yang has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Bin Li
State Key Laboratory of Respiratory Disease, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China
124 shared publications - Jiao-Jiao Xu
Guangzhou Medical University 1 Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, The Affiliated Traditional Chinese Medicine Hospital, The Fifth Affiliated Hospital Guangzhou, China
124 shared publications - Chun-Miao Deng
Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
102 shared publications - Fan Zhang
The Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University Guangzhou China
102 shared publications - Guo-Geng Zhang
Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, State Key Laboratory of Respiratory Disease, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
102 shared publications - Qin-Wen Liu
Neurosurgery Center Department of Cerebrovascular Surgery Engineering Technology Research Center of Education Ministry of China on Diagnosis and Treatment of Cerebrovascular Disease Zhujiang Hospital Southern Medical University Guangzhou 510282 P. R. China
102 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Phase Separation of ZBED2 Stabilizes ILK to Drive Metastasis and Immune Evasion in Esophageal Squamous Cell Carcinoma
NAT10 modulates ac4C modification and stability of ZBED2 mRNA.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Phase Separation of ZBED2 Stabilizes ILK to Drive Metastasis and Immune Evasion in Esophageal Squamous Cell Carcinoma
NAT10 modulates ac4C modification and stability of ZBED2 mRNA.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from Phase Separation of ZBED2 Stabilizes ILK to Drive Metastasis and Immune Evasion in Esophageal Squamous Cell Carcinoma
ZBED2 attenuates the cytotoxic activity of CD8+ T cells.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from Phase Separation of ZBED2 Stabilizes ILK to Drive Metastasis and Immune Evasion in Esophageal Squamous Cell Carcinoma
ZBED2 attenuates the cytotoxic activity of CD8+ T cells.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Phase Separation of ZBED2 Stabilizes ILK to Drive Metastasis and Immune Evasion in Esophageal Squamous Cell Carcinoma
ILK–STAT3 induces PD-L1 expression.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Phase Separation of ZBED2 Stabilizes ILK to Drive Metastasis and Immune Evasion in Esophageal Squamous Cell Carcinoma
ILK–STAT3 induces PD-L1 expression.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Phase Separation of ZBED2 Stabilizes ILK to Drive Metastasis and Immune Evasion in Esophageal Squamous Cell Carcinoma
IPA reveals ZBED2-activated ILK signaling.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Phase Separation of ZBED2 Stabilizes ILK to Drive Metastasis and Immune Evasion in Esophageal Squamous Cell Carcinoma
IPA reveals ZBED2-activated ILK signaling.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S12 from Phase Separation of ZBED2 Stabilizes ILK to Drive Metastasis and Immune Evasion in Esophageal Squamous Cell Carcinoma
The NAT10-ZBED2-HSP90AA1 axis activates PD L1 expression transcriptionally.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S12 from Phase Separation of ZBED2 Stabilizes ILK to Drive Metastasis and Immune Evasion in Esophageal Squamous Cell Carcinoma
The NAT10-ZBED2-HSP90AA1 axis activates PD L1 expression transcriptionally.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Phase Separation of ZBED2 Stabilizes ILK to Drive Metastasis and Immune Evasion in Esophageal Squamous Cell Carcinoma
ZBED2 LLPS promotes HSP90A1 transcription via promoter–enhancer interaction.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Phase Separation of ZBED2 Stabilizes ILK to Drive Metastasis and Immune Evasion in Esophageal Squamous Cell Carcinoma
ZBED2 LLPS promotes HSP90A1 transcription via promoter–enhancer interaction.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Phase Separation of ZBED2 Stabilizes ILK to Drive Metastasis and Immune Evasion in Esophageal Squamous Cell Carcinoma
LLPS is indispensable for ZBED2-mediated ESCC metastasis.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Phase Separation of ZBED2 Stabilizes ILK to Drive Metastasis and Immune Evasion in Esophageal Squamous Cell Carcinoma
LLPS is indispensable for ZBED2-mediated ESCC metastasis.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Phase Separation of ZBED2 Stabilizes ILK to Drive Metastasis and Immune Evasion in Esophageal Squamous Cell Carcinoma
ZBED2 promotes ESCC invasion and metastasis via ILK signaling.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Phase Separation of ZBED2 Stabilizes ILK to Drive Metastasis and Immune Evasion in Esophageal Squamous Cell Carcinoma
ZBED2 promotes ESCC invasion and metastasis via ILK signaling.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Phase Separation of ZBED2 Stabilizes ILK to Drive Metastasis and Immune Evasion in Esophageal Squamous Cell Carcinoma
HSP90AA1 is essential for ZBED2 function in ESCC metastasis.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Phase Separation of ZBED2 Stabilizes ILK to Drive Metastasis and Immune Evasion in Esophageal Squamous Cell Carcinoma
HSP90AA1 is essential for ZBED2 function in ESCC metastasis.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Phase Separation of ZBED2 Stabilizes ILK to Drive Metastasis and Immune Evasion in Esophageal Squamous Cell Carcinoma
ILK diminishes CD8+ T cell activity in vitro and in vivo.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Phase Separation of ZBED2 Stabilizes ILK to Drive Metastasis and Immune Evasion in Esophageal Squamous Cell Carcinoma
ILK diminishes CD8+ T cell activity in vitro and in vivo.